

Introduction

Note: This PDF is intended to be used as a worksheet. Survey responses must be submitted in Qualtrics using the link in your invitation email

ACHA SEXUAL HEALTH SERVICES SURVEY 2020

American College Health Association

Sexual Health Services Survey for Calendar Year 2019 with additional 2018 Prevalence Data

Thank you for taking the time to complete this survey. We have changed the name of the ACHA Pap Test and STI Survey to the Sexual Health Services Survey in an effort to be more inclusive and more accurately reflect the information collected. The ACHA Sexual Health Education and Clinical Care Coalition has made significant revisions to the survey to make it as concise and easy-to-follow as possible. The objective of this survey is to track modes of management and outcomes of evaluation to serve as both a benchmark and database of comparable statistics.

All data collected in this survey is in reference to Calendar Year 2019 (January 1 – December 31, 2019). Please answer with respect to services you provided and policies that were in place in CY2019, rather than current policies or practices. If there were different policies in place between the spring and fall semesters, please reference the Fall 2019 policies. Where indicated, we are also requesting CY2018 prevalence data (January 1- December 31, 2018). CY2018 data requests are noted in this color.

Please submit only objective data except as specified. Please leave blank unanswerable questions or questions that are not applicable to your health services.

We must have both the numerator (number of positives) and denominator (number tested) to calculate the positivity rate. If you only have data for positive STI tests without the total number of students tested, we will not be able to use your data for these items. *Please leave these items blank if you do not have both numbers.*

Use only whole numbers in your numerical entries (no commas).

If you'd like to view the full survey, or print a copy, please click here.

Contacts and Demographics

Contact and Demographics

Name of College/University: \$\{m://SCHOOL\}

1) Name of person completing this survey:

2) Title of person completing this survey:					
2)	E mail adduces for gr				
3)	E-mail address for qu	lestions about survey entries:			
4)	Telephone number of	f respondent:			
5)	Which best describes	your <u>primary</u> role in college health?			
0	Administrator				
0	Healthcare Provider				
0	Information Technology	y or Data Management			
0	Health Education/Prom	otion Professional			
0	Other (please specify)				
-	-	alth center provide clinical sexual health services (e.g., PAP/STI testing, pregnancy			
Not		rEP, PEP, HPV vaccinations, etc.)? Delow, the survey will end for you. Please do not select "No" unless you do not plan ne survey.			
0	Yes				
0		No (please provide any additional information in the box below)			
7)	College Health Cente	r demographic information (for the percentages enter a whole number only)			
	0	Total number of student medical visits to your Health Center 2019			
	0	% female visits			

0	% male visits	
0	% transgender or gender non-conforming	visits
-	019 (GYN exam, annual/well woman exa re conducted in the following clinical sett	
	Yes	No
Primary Care	0	0
Clinic dedicated to GYN or Sexual Health	Ο	0
Other (please specify)	0	0
Cervical Cancer Screening	eening and Management	
	management assumptions about standard of c	care are based on the following:
Guidelines for the Managemen Saslow D, Solomon D, Lawson	t of Women with Abnormal Cervical Cancer Sc H, et al. (2012).	reening Tests
• •	rican Society for Colposcopy and Cervical Path s for the Prevention and Early Detection of Cer	
	, wt al. (2013). 2012 Updated Consensus Guid and cancer precursors. <i>Journal of Lower Geni</i>	_
For more information go to: ht	tp://www.asccp.org/asccp-guidelines	
9) Does your student healt	h center offer cervical cytology screening	g tests?
O Yes		
O No		

10) For each age group, indicate whether or not this cervical cytology screening test was offered for female persons or persons with a cervix at your health center in 2019. (Note that there are 3 questions for each row. Please provide a response for all 3 age groups in each row)

		Ages	21-24	Ages	25-29	Ages	30-65
		Yes	No	Yes	No	Yes	No
Conventional slide		0	0	0	0	0	0
Liquid-based cytology, alone		0	0	0	0	0	0
Liquid-based cytology with refl	lex HPV testing for ASC-US or LSIL	0	0	0	0	0	0
Liquid-based cytology with HP	V "co-testing"	0	0	0	0	0	0
11) Please indicate which o at your Health Center in 20	f the following cervical disease manag 19.	ement m	odaliti	es wer	e provi	ided in-	house
	Provided at our Health Center	Not p				Center (p provider)	
Colposcopy	0				0		
Cryotherapy	0				0		
Laser ablation/LEEP	0				0		
Other (please specify)	0				0		
12) For women under age 2	25, what was your Health Center's usu	al practi	ce for 1	manage	ement (of a firs	t
= -	l as atypical squamous cells of undeter	_					
O HPV DNA test (reflex or ot	therwise)						
O Repeat Pap in 6 months							
O Repeat Pap in 12 months							
O Immediate colposcopy							
O Varied by provider, no star	ndard practice						
O Don't know							
through G are mutually exc	cal Pap test results for January 1, 2019 lusive and SHOULD SUM TO EQUAL TH e sure to enter data in A-G below so th	E TOTAL	REPOF	RTED at	the bo	ottom r	ow
<u>2019</u>				_			
A. Number reported as norma	al				0		
B. Number reported as ASC-U	JS (atypical squamous cells of undetermined	significar	nce)		0		

C. Number reported as LSIL (low-grade squamous intraepithelial lesion)					
or realiser reported as 2012 (for grade squamous intraopterional resion)	0				
D. Number reported as ASC-H, Low-grade, cannot exclude high-grade or HSIL or CIS (atypical squamous cells: cannot exclude high-grade, high-grade squamous intraepithelial lesion)					
E. Number reported as AGC or CIS (atypical glandular cells or carcinoma in situ)					
F. Number reported as unsatisfactory (no dx)	0				
G. Number reported as other dx, not listed above	0				
Total	0				
2019					
Number reported with no endocervical cells present (with any of					
hrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED	at the bottom				
through G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result.	at the bottom				
L3C) Summary of all Cervical Pap test results for January 1, 2018-December 31, 201 chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal	at the bottom				
through G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018	at the bottom correct rates f				
chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal	at the bottom e correct rates for				
chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal B. Number reported as ASC-US (atypical squamous cells of undetermined significance)	0 at the bottom e correct rates for 0 0				
chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal B. Number reported as ASC-US (atypical squamous cells of undetermined significance) C. Number reported as LSIL (low-grade squamous intraepithelial lesion) D. Number reported as ASC-H, Low-grade, cannot exclude high-grade or HSIL or CIS (atypical)	0 0 0				
chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal B. Number reported as ASC-US (atypical squamous cells of undetermined significance) C. Number reported as LSIL (low-grade squamous intraepithelial lesion) D. Number reported as ASC-H, Low-grade, cannot exclude high-grade or HSIL or CIS (atypical squamous cells: cannot exclude high-grade squamous intraepithelial lesion)	0 0 0 0				
chrough G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED abeled TOTAL. Please make sure to enter data in A-G below so that we can calculate category of test result. 2018 A. Number reported as normal B. Number reported as ASC-US (atypical squamous cells of undetermined significance) C. Number reported as LSIL (low-grade squamous intraepithelial lesion) D. Number reported as ASC-H, Low-grade, cannot exclude high-grade or HSIL or CIS (atypical squamous cells: cannot exclude high-grade squamous intraepithelial lesion) E. Number reported as AGC or CIS (atypical glandular cells or carcinoma in situ)	0 0 0 0				

13D) Summary of all Cervical Pap test results for January 1, 2018-December 31, 2018. Please leave this question blank if you don't know.

	Number reported with <u>no endocervical cells present</u> (with any dx above)					
Anal Cytology						
Anal Cytology Screen	ning					
14) Did your health center p Select all that apply.	provide anal cytology screening for any of the following individuals in 2019?					
2019						
☐ Females						
Males						
☐ Transgender☐ Unknown/gender unspecifie	ed.					
_	al cytology at our Health Center					
☐ I don't know						
14A) If yes, number of anal 2019	cytology tests performed in 2019:					
0	Number of females					
U	Number of females					
0	Number of males					
0	Number of transgender					
	Trainber of danagender					
0	Number of unknown/gender unspecified					
14B) Did your health center provide anal cytology screening for any of the following individuals in 2018? Select all that apply.						
	provide and cycology screening for any of the following mulviduals in 2010:					
2018	provide and cycology screening for any of the following mulviduals in 2010:					
2018 ☐ Females	provide anal cycology screening for any of the following mulviduals in 2010:					

☐ Transgender ☐ Unknown/gender unspecifie ☐ None, we don't perform and ☐ I don't know	ed al cytology at our Health Center						
14C) If yes, number of anal	cytology tests performed in 2018	B:					
2018							
0	Number of females						
0	Number of males						
0	Number of transgender						
0	Number of unknown/gender unspecif	ied					
STI Testing STI Testing 15) Did your health center rasymptomatic patients?	equire a provider (MD, NP, PA) vis	it in 20	019 fe	or STI	scree	ning (i.e. la	abs) in
O Yes, in all asymptomatic pa	tients for STI(s)						
O Yes, in some asymptomatic	patients for some STI(s)Yes						
O No, we do not require a pro	ovider visit for any STI screening labs in	any a	sympt	omatic	patier	nts	
O No, STI screening was not	provided for any students at our health	center					
O I don't know							
-	of the following STI(s) screening wo for asymptomatic patients? (Note r all 3 groups in each row)	-				-	_
		Mā	ale	Fem	nale		as neither r female
		Yes	No	Yes	No	Yes	No
Chlamydia	0	0	0	0	0	0	

	Ma	ıle	Fem	nale	Identify as male or f	
	Yes	No	Yes	No	Yes	No
Gonorrhea	0	0	0	0	0	0
HIV	0	0	0	0	0	0
Syphilis	0	0	0	0	0	0
Other (specify):	0	0	0	0	0	0
16A) Chlamydia testing	_					
Note that bottom number must be less than or equal to the top	numt	er				
<u>2019</u>						
Number of unique (unduplicated) female patients under age 24 seen at your health center in 2019. Number of unique (unduplicated) female patients under age 24 tested for chlamydia at your health center in 2019.						
16B) Chlamydia testing						
Note that bottom number must be less than or equal to the top	numb	er				
2018						
Number of unique (unduplicated) female patients under age 24 seen at your health center in 2018.						
Number of unique (unduplicated) female patients under age 24 tested for chlamydia at your health center in 2018.						
17A) What type of specimen did your Health Center usually/prefemales in 2019? (select one)	eferen	tially	collec	ct for	chlamydia te	esting in
O Cervical swab						
O Vaginal swab-Patient collected						
O Vaginal swab-Clinician collected						
O Urine						
O Varies						
O None						

17B) What type of specimen did your Health Center usually/preferentially collect for chlamydia testing in males in 2019? (select one)

O Urethra	al swab							
O Urine								
O Varies								
O None								
_			your Health Co s male or fema		_	ly collect fo	r chlamydia t	esting in
O Cervica	al swab							
O Vagina	l swab-Patien	t collected						
O Vagina	l swab-Clinicia	n collected						
O Urethra	al swab							
O Urine								
O Varies								
O None								
18) Did your health center routinely include pharyngeal and rectal tests for chlamydia and gonorrhea when screening the following groups for STIs in 2019? (Note that there are 4 questions for each row. Please provide a response for all 4 groups in each row)								
	Men who with		Women who l		Women who		Men who ha	
	Yes	No	Yes	No	Yes	No	Yes	No
Chlamydia	0	0	0	0	0	0	0	0
Gonorrhea	0	0	0	0	0	0	0	0
O All test insurar O Some insurar O All test	vice in 2019' s/visits were once) tests/visits wence)	? (select or charged to the charged to the charged to the selection)	he patient or the out others are fi tudent (there wable	eir insurance (ti ree (there was s	nere was alwa sometimes a c	ys a cost to t	he patient or their	·

_	What types of HIV antibody tests did your Health Center usually/preferenti 2019? (select one)	ally collect to scre	en for HIV
0	Laboratory test, blood		
0	Laboratory test, oral fluid		
0	Rapid test, blood		
0	Rapid test, oral fluid		
0	None		
0	Other (please specify)		
21)	Does your health center have providers that prescribe PrEP (Pre-Exposure I	Prophylaxis) when	indicated?
0	Yes		
0	No		
0	I don't know		
21A	A) For those who prescribed PrEP in CY 2019, what percent were the following	ng:	
Plea	ase be sure your total is either 0% or 100%.		
Me	en who have sex with men	0	%
Нє	eterosexual men	0	%
He	eterosexual women	0	%
Pe	eople who inject drugs	0	%
Ot	ther (please specify)	0	%
То	otal	0	%
	3) For those patients who were initiated on PrEP in 2019, what percent reture ointment:	ned for a 3-month	ı follow-up
0	0-24%		
0	25-49%		
0	50-74%		
O	75-99%		

21C app		PrEP in 2019, what were the barriers to prescribing: (please select all that							
	Lack of training/knowledge								
	Lack of administrative support								
	We don't prescribe any medications								
	Religious objections								
		Other (please specify)							
22)	Did your Health Center offe	er <u>non-occupational</u> PEP (Post-Exposure Prophylaxis) in 2019?							
0	Yes								
0	No								
0	I don't know								
_	What laboratory test did yection in 2019? (select one)	our Health Center usually/preferentially use to diagnose genital herpes :							
infe									
infe	ection in 2019? (select one)								
infe	ection in 2019? (select one) Viral culture	:							
infe	viral culture PCR	:							
infe	viral culture PCR Type specific serology (antibo	:							
infe	viral culture PCR Type specific serology (antibo	:							
0 0 0	viral culture PCR Type specific serology (antibo	: dy testing)							
0 0 0	viral culture PCR Type specific serology (antibo	: dy testing)							
infe	viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis							
infe	Viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your ection in women in 2019? (see the content of the c	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis							
infe	viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your ection in women in 2019? (see Microscopy (wet prep)	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis							
infe	viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your ection in women in 2019? (stank of the color of the col	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis select one)							
24) infe	Viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your ection in women in 2019? (stank of the color of the col	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis select one)							
infe	viral culture PCR Type specific serology (antiboth Antigen tests Tzank smears What type of test did your ection in women in 2019? (stank of the color of the col	dy testing) Other (please specify) Health Center usually/preferentially use for the diagnosis of trichomoniasis select one)							

O 100%

STI Test Results

Instructions: Please make sure to enter corresponding data in questions below so that we can calculate positivity rates by sex.

For sex, use sex assigned at birth for those not identifying as transgender. If you do not collect data by sex, please report totals in the "unknown" category for each infection. The number of positive test results must always be equal to or less than the number of tests done for each infection. All data applies to tests performed by your health service in calendar years 2019 or 2018. For each question, 2019 data is followed by the same question for 2018 data (in red). All items are labeled with the year they refer to. We must have both the numerator (number of positives) and denominator (number tested) to cacluate the positivity rate. If you only have data for positive STI tests without the number of students tested, we will not be able to use your data. Please leave number of positive STI tests blank if you cannot provide the number of students tested.

25A) Number of Gonorrhea tests performed, by sex in 2019

2019

0	Females
0	Males
0	Transgender
0	Unknown/unspecified gender

25B) Number of Gonorrhea tests positive, by sex in 2019

2019

0	Females
0	Males
0	Transgender
0	Unknown/unspecified gender

26A) Number of Gonorrhea tests performed, by sex in 2018 **2018** 0 Females 0 Males 0 Transgender 0 Unknown/unspecified gender 26B) Number of Gonorrhea tests positive, by sex in 2018 **2018** 0 Females 0 Males 0 Transgender 0 Unknown/unspecified gender 27A) Number of Chlamydia tests performed, by sex in 2019 <u>2019</u> 0 Females 0 Males 0 Transgender

Unknown/unspecified gender

0


27B) Number of Chlamydia tests positive, by sex in 2019			
2019			
0	Females		
0	Males		
0	Transgender		
0	Unknown/unspecified gender		
28A) Number of Chlamydia t	tests performed, by sex in 2018		
0	Females		
0	Males		
0	Transgender		
0	Unknown/unspecified gender		
28B) Number of Chlamydia t	tests positive, by sex in 2018		
0	Females		
0	Males		
0	Transgender		
0	Unknown/unspecified gender		

<u> 2019</u>

0	Females
0	Males
0	Transgender
0	Unknown/unspecified gender


29B) HIV antibody tests positive, by sex in 2019

<u> 2019</u>




30A) HIV antibody tests performed, by sex in 2018

2018




30B) HIV antibody tests positive, by sex in 2018




31A) Syphilis tests performed, by sex in 2019

<u> 2019</u>



31B) Syphilis tests positive, by sex in 2019

<u> 2019</u>



32A) Syphilis tests performed, by sex in 2018

0	Females		
0	Males		
0	Transgender		
0	Unknown/unspecified gender		
32B) Syphilis tests positive	, by sex in 2018		
0	Females		
0	Males		
0	Transgender		
0	Unknown/unspecified gender		
33) Herpes viral culture or PCR tests performed in 2019 (genital sites only): 2019			
0	Females		
0	Males		
0	Individuals who do not identify as either male or female		
34) <u>Total</u> Herpes viral culture or PCR tests performed in 2019 (genital sites only): 2019			
Total number positive for HSV	7-2	0	
Total number positive for HSV	Total number positive for HSV-1		

Total number positive type unknown	0
Total	0
35A) Herpes viral culture or PCR tests performed in 2019	
Please double check that your total in 35 is equal to or less	s than the total you reported for <u>females</u> in 3
<u>2019</u>	
Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	0
Total	0
35B) Herpes viral culture or PCR tests performed in 2019	for <u>males</u> (genital sites only):
Please double check that your total in 36 is equal to or less	s than the total you reported for <u>males</u> in 33.
2019	
Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	0
Total	0
35C) Herpes viral culture or PCR tests performed in 2019 or female (genital sites only):	for individuals who <u>do not identify as either i</u>
Please double check that your total in 34 is equal to or less not identify as either male or female in 33.	s than the figure you reported for those who
<u>2019</u>	
Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	0

п	
	MA

0

36) Herpes viral culture or PCR tests performed in 2018 (genital sites only):

2018

0	Females
0	Males
0	Individuals who do not identify as either male or female

37) Total Herpes viral culture or PCR tests performed in 2018 (genital sites only):

2018

Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	0
Total	0

38A) Herpes viral culture or PCR tests performed in 2018 for females (genital sites only):

Please double check that your total in 35A is equal to or less than the total you reported for females in 33.

2018

Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	0
Total	0

38B) Herpes viral culture or PCR tests performed in 2018 for males (genital sites only):

Please double check that your total in 36A is equal to or less than the total you reported for <u>males</u> in 33.

	-	-	
•	•	п	>

38C) Herpes viral culture or PCR tests performed in <u>2018</u> for individuals who <u>do not identify as either male or female</u> (genital sites only): Please double check that your total in 34 is equal to or less than the figure you reported for those who <u>do</u>			
Total	0		
Total number positive type unknown	0		
Total number positive for HSV-1	0		
Total number positive for HSV-2	0		

2018

Total number positive for HSV-2	0
Total number positive for HSV-1	0
Total number positive type unknown	
Total	0

39A) How many patients did your Health Center diagnose with trichomoniasis in 2019?

2019



39B) How many patients did your Health Center diagnose with trichomoniasis in 2018?

2018



40A) How many patients did your Health Center diagnose with bacterial vaginosis in 2019?

	0	Patients
ND) Have m		d very Health Contag diagnose with heaterial verinesis in 20192
	iany patients di	d your Health Center diagnose with bacterial vaginosis in 2018?
18		
	0	Patients
A) Numb	er of unduplicat	ed patients diagnosed with genital warts in 2019:
<u>19</u>		
	0	Females
	0	Males
	0	Transgender
	0	Unknown/unspecified gender
.B) Numb 18	er of unduplicat	ted patients diagnosed with genital warts in 2018:
	0	Females
	0	Males
	0	Transgender
	0	Unknown/unspecified gender

42) 201	Did providers (MD, NP, P 9?	A) at you	ır Health Cente	er prescribe hor	rmone therapy	for transgend	ler patients in
0	Yes						
0	No						
0	I don't know						
42A	(a) In 2019, we offered the	e followin	g hormone the	erapy for transo	gender patients	s:	
0	Initiated therapy only						
0	Initiated and continued the	rapy					
0	Continued therapy only						
	B) What were barriers to p t apply)	prescribir	ng hormone the	erapy for transo	gender patient	s in 2019? (pl	ease select all
	Lack of training/knowledge						
	Lack of administrative supp	ort					
	We don't prescribe any med	dications					
	Religious objections						
		Other (ple	ease specify)				
_	Do the laws in the state vide expedited partner th	_		_			it providers to
			Yes; it is permitted and prescribed by providers	No; it is permitted but not prescribed by providers	No; it is legal in our state but not permitted per clinic policy	No, EPT is not legal in our state for this STI	I Don't Know
Chl	amydia		0	0	0	0	0
Goı	norrhea		0	0	0	0	0
Syp	philis		0	0	0	0	0
Tric	chomoniasis		0	0	0	0	0
O+k	oor (specify)						

0

0

0 0

0

"In 2019, patients at our health or wellness center regularly voiced concerns that their parent(s) may find out that they received testing, screening, or treatment for a sexually transmitted infection (STI), including HIV."				
O Strongly agree				
O Agree				
O Neutral/Indifferent				
O Disagree				
O Strongly disagree				
45) In 2019, did your state law allow students to have their explanation to them?	n of benefit	(EOB) forr	ns sent directly	
O Yes				
O No				
O I don't know				
46) Regarding STIs and patient confidentiality concerns, please indicate were used in your center between January 1 and December 31, 2019.	te which of t	the followin	ng procedures	
	Yes	No	I don't know	
We offered anonymous and/or confidential HIV testing.	0	0	0	
We referred patients to other health care providers that offered confidential screening, testing, or treatment for free or reduced cost.	0	0	0	
Student health fees covered STI/HIV testing, screening, and/or treatment services, so there was no additional cost to students.	0	0	0	
We (or another university office) hosted at least one campus testing event that offered free and anonymous and/or confidential testing. (e.g., Get Yourself Talking, Get Yourself Tested).	0	0	0	
Patients could pay for testing, screening, or treatment out of pocket to avoid having an explanation of benefits (EOB) form generated.	0	0	0	
	Yes	No	I don't know	
We did not generate EOB forms as we do not bill third-party health insurance.	0	0	0	
We billed third-party health insurance using more general billing codes.	0	0	0	
We explained to patients that receiving any testing, screening, or treatment was not confidential and may be revealed on EOB forms that are sent to insurance policy holders.	0	0	0	
EOB forms were sent directly to students' local addresses.	0	0	0	
We did not have any of the above procedures in place.	0	0	0	

-	ening, or treatment:
_	On which of the following topics did your health center provide information to students in 2019? This udes any clinical service, health education sessions, etc. (Check all that apply)
	Abstinence
	Consent
	Contraception
	Emergency Contraception
	External (male) condom use
	Fertility awareness methods
	General family planning/Preconception
	Healthy Relationships
	Gender Identity and Sexual Orientation
	Internal (female) condom use
	Sexual assault awareness/prevention
	STI/HIV prevention
	Other (please specify)
٥,	Was OTC For some or Contraction (Plan R) considered through constitution to lead the Considering 20102
	Was OTC Emergency Contraception (Plan B) available through your Student Health Service in 2019?
\mathcal{L}	Yes, for free
))	Yes, at some cost
\mathcal{O}	Yes, both free and at some cost
J	No, it was not available for students through our Student Health Service
_	Was prescription Emergency Contraception (Ella) provided through your Student Health Service in 9?
0	Yes, it was prescribed by our clinicians and dispensed through SHS
2	Yes, it was prescribed by our clinicians but not dispensed through SHS
0	No, it was not prescribed by our clinicians or dispensed through SHS

Yes, it was provided through our SHS for Emergency Contraception					
No, it was not provided through our SHS for Emergency Contraception; patients are referred to outside provider					
O No, it was not provided the outside provider					
Please answer the followin methods through your Stud	g questions about th dent Health Service i	e availability of safer n 2019:	sex products and c	contraceptive	
52A) OTC Items	How we	re the following items	s made available to	students in 2019?	
	For free	At some cost	Both free and at some cost	Item not available to students	
Female (internal) condom	0	0	0	0	
Latex, or non-latex dams (i.e., dental or oral dams)	0	0	0	0	
Latex, or non-latex gloves	0	0	0	0	
Lubricant	0	0	0	0	
Male (external) condom	0	0	0	0	
Spermicides (suppositories, foams, jellies and vaginal contraceptive film)	0	0	0	0	
52B) RX/Patient-administeresponse for both question	ered methods (Note t	hat there are 2 quest	ions for each row.	Please provide a	
esponse for both question	Was the medication	n/device prescribed by ider in 2019?		on/device dispensed SHS in 2019?	
	Yes	No	Yes	No	
Cervical Cap	0	0	0	0	
Contraceptive Patch	0	0	0	0	
Contraceptive Ring	0	0	0	0	
Diaphragm	0	0	0	0	
Oral contraceptives (combined and mini pill)	0	0	0	0	

51) Was copper IUD for Emergency Contraception (Paragard) provided through your Student Health Service

in 2019?

52C) RX/Provider-administered methods (Note that there are 2 questions for each row. Please provide a response for both questions in each row)

	Was the medication/device/procedure provided at the SHS in 2019?		Were interested students referred off-campus for medication/device/procedure in 2019?			
	Yes	No	Yes	No		
Depo Provera	0	0	0	0		
Essure	0	0	0	0		
Implants (Implanon/Nexplanon)	0	0	0	0		
Intrauterine devices (hormonal or copper)	0	0	0	0		
Tubal Ligation	0	0	0	0		
Vasectomy	0	0	0	0		
2019	Number performed					
2019						
	Number positive					
53B) For pregnancy tests performed at your health center between January 1, 2018 to December 31, 2018 (in-house or sent out, either urine or blood): Please double check that your number of positive tests is not greater than the number of tests performed.						
<u>2018</u>						
	Number performed					
	Number positive					

54) For students with a positive pregnancy test, what services were available from your Health Center in 2019?

No, not permitted due to legal limitations in our state

	Yes	No	No, not permitted due to legal limitations in our state	No, not permitted due to school policy
"All options" counseling and education	0	0	0	0
Limited counseling and education	0	0	0	0
Referral for adoption services	0	0	0	0
Referral for abortion services	0	0	0	0
Referral for prenatal care	0	0	0	0
Medical abortion services provided at SHS	0	0	0	0
Prenatal care provided at SHS	0	0	0	0
O Yes, for some patients during O No, we do not use chaperones O I don't know 56) Did your organization's (elements of the patient's gender identity and so	for any examination	ons or procedures record provide stand	dard options for colle	•
patient's gender identity <u>and</u> so	ex assigned at bi	rth in 2019? (Free-f	form notes would not	count.)
O Yes				
O No				
O I don't know				
57) Did your organization's (ele sexual orientation in 2019? (fre	-	-		-
O Yes				
O No				
O I don't know				

The End

Contact Mary Hoban at ACHA for specific questions about this survey.	Thank you for taking the time to
complete this survey.	

When you hit the "submit" button below, your responses will be recorded and a summary of your submission will be displayed. You may download a PDF of your submission for your records.

Powered by Qualtrics